S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Trevena Stock Forecast, Price & News

-0.04 (-8.73%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
22.39 million shs
Average Volume
2.39 million shs
Market Capitalization
$69.19 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

TRVN Stock Forecast (MarketRank)

Overall MarketRank

1.78 out of 5 stars

Medical Sector

823rd out of 1,417 stocks

Pharmaceutical Preparations Industry

407th out of 675 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Trevena logo

About Trevena (NASDAQ:TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

TRVN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$-51.59 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$570 thousand
Book Value
$0.39 per share


Free Float
Market Cap
$69.19 million

Trevena Frequently Asked Questions

Should I buy or sell Trevena stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Trevena stock.
View analyst ratings for Trevena
or view top-rated stocks.

What is Trevena's stock price forecast for 2022?

2 equities research analysts have issued 1-year price targets for Trevena's stock. Their TRVN stock forecasts range from $3.50 to $6.00. On average, they expect Trevena's share price to reach $4.75 in the next year. This suggests a possible upside of 1,036.4% from the stock's current price.
View analysts' price targets for Trevena
or view top-rated stocks among Wall Street analysts.

How has Trevena's stock performed in 2022?

Trevena's stock was trading at $0.5830 at the beginning of 2022. Since then, TRVN shares have decreased by 28.3% and is now trading at $0.4180.
View the best growth stocks for 2022 here

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Trevena

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its earnings results on Wednesday, May, 11th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.65 million. Trevena had a negative net margin of 7,771.74% and a negative trailing twelve-month return on equity of 82.39%. During the same period last year, the business posted ($0.06) EPS.
View Trevena's earnings history

Who are Trevena's key executives?

Trevena's management team includes the following people:
  • Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 59, Pay $920.39k) (LinkedIn Profile)
  • Mr. Barry Shin, Sr. VP & CFO (Age 50, Pay $609.94k)
  • Dr. Mark A. Demitrack, Sr. VP & Chief Medical Officer (Age 64, Pay $641.3k)
  • Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Michael Catalano, VP of Marketing
  • Mr. Robert T. Yoder, Sr. VP, Chief Bus. Officer & Head of Commercial Operations (Age 56)
  • Ms. Patricia M. Drake, Sr. VP & Chief Commercial Officer (Age 56)

What other stocks do shareholders of Trevena own?

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.58%), Vanguard Group Inc. (4.28%), State Street Corp (1.66%), Northern Trust Corp (0.84%), GSA Capital Partners LLP (0.52%) and Renaissance Technologies LLC (0.19%).
View institutional ownership trends for Trevena

Which institutional investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Goldman Sachs Group Inc., Bank of America Corp DE, BlackRock Inc., Group One Trading L.P., Northern Trust Corp, and State Street Corp.
View insider buying and selling activity for Trevena
or view top insider-selling stocks.

Which institutional investors are buying Trevena stock?

TRVN stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Captrust Financial Advisors, Renaissance Technologies LLC, and Simplex Trading LLC.
View insider buying and selling activity for Trevena
or or view top insider-buying stocks.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.42.

How much money does Trevena make?

Trevena (NASDAQ:TRVN) has a market capitalization of $69.19 million and generates $570 thousand in revenue each year. The biopharmaceutical company earns $-51.59 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for Trevena is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].

This page (NASDAQ:TRVN) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.